Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
ARCT
Top 10 Correlated ETFs
ARCT
Top 10 Correlated Stocks
ARCT
In the News
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Kyle Gutsadt - Investor Relations Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Padmanabh Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Seamus Fernandez - Guggenheim Yigal Nochomovitz - Citi Pete Stavropoulos - Cantor Fitzgerald Yale Jen - Laidlaw and Company Yanan Zhu - Wells Fargo Securities Operator Good day ladies and gentlemen and welcome to the Arcturus Therapeutics Third Quarter 2022 Earnings Call. Today's conference is being recorded.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics to Present at the Following Investor Conferences in November
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Arcturus Therapeutics Stock Is Skyrocketing Today
Investors are applauding Arcturus' collaboration with CSL.
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
A strategic collaboration has today's traders talking about Arcturus Therapeutics (NASDAQ: ARCT ) and CSL (OTCMKTS: CSLLY ). Reportedly, the two companies will work together on mRNA technology for a wide variety of applications.
Arcturus Therapeutics to Attend the Following Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences. Jefferies Cell and Genetic Medicine Summit (Attending) Thursday – Friday, September 29 – 30, 2022 Cantor Neurology &am
7 Small-Cap Stocks to Buy on the Dip or You'll Be Kicking Yourself Later
With several worrying developments domestically and internationally, many investors chose to rush for the exits, though a brave few may have opportunities in small-cap stocks to buy on the dip. Tethered to small-capitalization companies, these market ideas don't always grab the spotlight.
Acrturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2022 Results - Earnings Call Transcript
Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - Chief Scientifc Officer and Chief Operating Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Nick Abbott - Wells Fargo Kumaraguru Raja - Brookline Capital Markets Yale Jen - Laidlaw and Company Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Operator Good day and welcome to the Arcturus Therapeutics Second Quarter 2022 Financial Update and Pipeline Progress Call. Today's conference is being recorded.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.21 | 1.56 | 1.72 | 0.47 | 0.47 | |
| Net income per share | -3.53 | -2.16 | -2.15 | -3.55 | -7.74 | |
| Operating cash flow per share | -0.15 | -2.06 | -0.53 | -2.11 | -5.13 | |
| Free cash flow per share | -0.23 | -2.21 | -0.6 | -2.2 | -5.26 | |
| Cash per share | 15.73 | 3.65 | 5.91 | 22.8 | 14.08 | |
| Book value per share | 10.95 | 1.35 | 2.14 | 19.53 | 8.67 | |
| Tangible book value per share | 10.95 | 1.35 | 2.14 | 19.53 | 8.67 | |
| Share holders equity per share | 10.95 | 1.35 | 2.14 | 19.53 | 8.67 | |
| Interest debt per share | 0.05 | 1 | 1.38 | 0.86 | 1.89 | |
| Market cap | 24.7M | 50.35M | 124.91M | 1.47B | 586.87M | |
| Enterprise value | -269K | 23.55M | 69.38M | 1.03B | 266.01M | |
| P/E ratio | -2.27 | -2.31 | -4.81 | -20.39 | -2.88 | |
| Price to sales ratio | 1.9 | 3.2 | 6.01 | 154.24 | 47.49 | |
| POCF ratio | -53.69 | -2.43 | -19.38 | -34.33 | -4.35 | |
| PFCF ratio | -34.73 | -2.26 | -17.2 | -32.99 | -4.24 | |
| P/B Ratio | 0.73 | 3.69 | 4.84 | 3.71 | 2.57 | |
| PTB ratio | 0.73 | 3.69 | 4.84 | 3.71 | 2.57 | |
| EV to sales | -0.02 | 1.49 | 3.34 | 107.47 | 21.52 | |
| Enterprise value over EBITDA | 0.03 | -1.12 | -2.84 | -14.55 | -1.31 | |
| EV to operating cash flow | 0.58 | -1.13 | -10.77 | -23.92 | -1.97 | |
| EV to free cash flow | 0.38 | -1.06 | -9.55 | -22.98 | -1.92 | |
| Earnings yield | -0.44 | -0.43 | -0.21 | -0.05 | -0.35 | |
| Free cash flow yield | -0.03 | -0.44 | -0.06 | -0.03 | -0.24 | |
| Debt to equity | 0 | 0.73 | 0.58 | 0.03 | 0.2 | |
| Debt to assets | 0.35 | 0.69 | 0.69 | 0.17 | 0.42 | |
| Net debt to EBITDA | 2.41 | 1.28 | 2.27 | 6.33 | 1.58 | |
| Current ratio | 4.61 | 3.33 | 3.48 | 9.45 | 3.81 | |
| Interest coverage | -69.95 | -117.26 | -29.87 | -86.07 | 0 | |
| Income quality | 0.04 | 0.95 | 0.25 | 0.59 | 0.66 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.58 | 1.31 | 0.61 | 2.43 | 3.35 | |
| Research and developement to revenue | 1.22 | 1.08 | 1.62 | 6.06 | 14.06 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.55 | 0.07 | 0.13 | 0.04 | 0.03 | |
| Capex to revenue | -0.02 | -0.09 | -0.04 | -0.18 | -0.28 | |
| Capex to depreciation | -0.61 | -2.54 | -1.2 | -1.98 | -2.85 | |
| Stock based compensation to revenue | 0.17 | 0.08 | 0.1 | 0.71 | 2.34 | |
| Graham number | 29.49 | 8.12 | 10.18 | 39.51 | 38.86 | |
| ROIC | -0.26 | -0.69 | -0.42 | -0.17 | -0.69 | |
| Return on tangible assets | -0.21 | -0.49 | -0.32 | -0.15 | -0.52 | |
| Graham Net | 9.95 | 0.94 | 1.38 | 18.94 | 7.92 | |
| Working capital | 39.83M | 29.25M | 52.97M | 418.27M | 279.42M | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | 32.64M | 11.27M | 17.94M | 387.89M | 214.36M | |
| Invested capital | 0 | 0.73 | 0.61 | 0.04 | 0.22 | |
| Average receivables | 1.3M | 3.3M | 2.15M | 2.13M | 2.75M | |
| Average payables | 6.28M | 6.59M | 8.28M | 10.77M | 10.42M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 13.48 | 103.83 | 38.26 | 81.31 | 99.44 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 27.08 | 3.52 | 9.54 | 4.49 | 3.67 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.32 | -1.6 | -1.01 | -0.18 | -0.89 | |
| Capex per share | -0.08 | -0.15 | -0.07 | -0.09 | -0.13 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.08 | 0.09 | 0.22 | 0.2 | 0.51 | |
| Net income per share | -2.07 | -2.05 | -1.47 | -1.94 | -1.33 | |
| Operating cash flow per share | -1.25 | -0.63 | -1.61 | -1.86 | -2.99 | |
| Free cash flow per share | -1.27 | -0.7 | -1.65 | -1.94 | -3.06 | |
| Cash per share | 16.47 | 15.71 | 14.06 | 12.12 | 8.98 | |
| Book value per share | 11.61 | 9.84 | 8.66 | 7 | 5.5 | |
| Tangible book value per share | 11.61 | 9.84 | 8.66 | 7 | 5.5 | |
| Share holders equity per share | 11.61 | 9.84 | 8.66 | 7 | 5.5 | |
| Interest debt per share | 2.61 | 2.58 | 1.88 | 2.65 | 3.44 | |
| Market cap | 890.77M | 1.26B | 975.55M | 711.1M | 392.24M | |
| Enterprise value | 525.29M | 911.79M | 654.69M | 460.62M | 245.52M | |
| P/E ratio | -4.08 | -5.82 | -6.31 | -3.47 | -2.78 | |
| Price to sales ratio | 445.16 | 516.38 | 168.37 | 135.6 | 29.34 | |
| POCF ratio | -27.04 | -75.57 | -22.96 | -14.5 | -4.95 | |
| PFCF ratio | -26.71 | -68.32 | -22.37 | -13.9 | -4.84 | |
| P/B Ratio | 2.91 | 4.86 | 4.27 | 3.85 | 2.69 | |
| PTB ratio | 2.91 | 4.86 | 4.27 | 3.85 | 2.69 | |
| EV to sales | 262.52 | 374.15 | 112.99 | 87.84 | 18.37 | |
| Enterprise value over EBITDA | -9.8 | -17.18 | -17.07 | -9.17 | -7.11 | |
| EV to operating cash flow | -15.95 | -54.75 | -15.41 | -9.39 | -3.1 | |
| EV to free cash flow | -15.75 | -49.5 | -15.01 | -9.01 | -3.03 | |
| Earnings yield | -0.06 | -0.04 | -0.04 | -0.07 | -0.09 | |
| Free cash flow yield | -0.04 | -0.01 | -0.04 | -0.07 | -0.21 | |
| Debt to equity | 0.2 | 0.18 | 0.2 | 0.23 | 0.43 | |
| Debt to assets | 0.32 | 0.4 | 0.42 | 0.46 | 0.5 | |
| Net debt to EBITDA | 6.82 | 6.53 | 8.37 | 4.99 | 4.25 | |
| Current ratio | 6.19 | 3.56 | 3.81 | 3.05 | 3.25 | |
| Interest coverage | -75.66 | -75.7 | 0 | -70.17 | 0 | |
| Income quality | 0.6 | 0.31 | 1.1 | 0.96 | 2.25 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 5.02 | 4.46 | 1.87 | 2.05 | 0.93 | |
| Research and developement to revenue | 22.83 | 18.63 | 5.63 | 8.56 | 2.82 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.11 | 0.03 | 0.04 | 0.02 | |
| Capex to revenue | -0.2 | -0.72 | -0.19 | -0.4 | -0.14 | |
| Capex to depreciation | -1.41 | -6.11 | -3.61 | -9.42 | -2.4 | |
| Stock based compensation to revenue | 3.77 | 2.82 | 1.3 | 1.41 | 1.25 | |
| Graham number | 23.27 | 21.32 | 16.9 | 17.49 | 12.85 | |
| ROIC | -0.14 | -0.17 | -0.13 | -0.21 | -0.17 | |
| Return on tangible assets | -0.12 | -0.12 | -0.1 | -0.15 | -0.12 | |
| Graham Net | 11.09 | 9.11 | 7.91 | 6.26 | 3.45 | |
| Working capital | 367.27M | 302.73M | 279.42M | 219.7M | 170.83M | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | 294.87M | 245.56M | 214.36M | 169.77M | 98.72M | |
| Invested capital | 0.22 | 0.26 | 0.22 | 0.37 | 0.62 | |
| Average receivables | 2.93M | 2.85M | 3.53M | 3.69M | 2.87M | |
| Average payables | 10.05M | 9.14M | 10.04M | 10.01M | 13.99M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 97.29 | 74.42 | 52.3 | 63.35 | 13.76 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.93 | 1.21 | 1.72 | 1.42 | 6.54 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.18 | -0.21 | -0.17 | -0.28 | -0.24 | |
| Capex per share | -0.02 | -0.07 | -0.04 | -0.08 | -0.07 |
Frequently Asked Questions
What is Arcturus Therapeutics Holdings Inc. stock symbol ?
Arcturus Therapeutics Holdings Inc. is a US stock , located in San diego of California and trading under the symbol ARCT
Is Arcturus Therapeutics Holdings Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $23. The lowest prediction is $14 and the highest is $30
What is ARCT stock prediction ?
With a median analyst target price of $25, 1 stock analysts have made 1 forecasts in last 90 days. $25 is the lowest and $25 is the greatest projection.
What is Arcturus Therapeutics Holdings Inc. stock quote today ?
Arcturus Therapeutics Holdings Inc. stock price is $16.09 today.
Is Arcturus Therapeutics Holdings Inc. stock public?
Yes, Arcturus Therapeutics Holdings Inc. is a publicly traded company.
Company Profile
- Volume Average 548.61K
- Market Capitalization 436.6M
- Employee 177
- CEO Mr. Joseph E. Payne M.Sc.
- Headquarters San Diego,CALIFORNIA,US
- IPO Date 2013-05-22
-
Website
https://arcturusrx.com 
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
